doxapram hydrochloride - Profile

What are the generic drug sources for doxapram hydrochloride and what is the scope of freedom to operate?

Doxapram hydrochloride is the generic ingredient in two branded drugs marketed by Hikma, Chartwell Injectable, and Watson Labs, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

Summary for doxapram hydrochloride

US Patents:	0
Tradenames:	2
Applicants:	3
NDAs:	3

US Patents and Regulatory Information for doxapram hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hikma	DOPRAM	doxapram hydrochloride	INJECTABLE;INJECTION	014879-001	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes
Chartwell Injectable	DOXAPRAM HYDROCHLORIDE	doxapram hydrochloride	INJECTABLE;INJECTION	076266-001	Jan 10, 2003	AP	RX	No	No
Watson Labs	DOXAPRAM HYDROCHLORIDE	doxapram hydrochloride	INJECTABLE;INJECTION	073529-001	Jan 30, 1992		DISCN	No	No

Last updated: July 31, 2026

ecutive summary: Doxapram hydrochloride is a mature respiratory stimulant with limited commercial upside and no evident active composition-of-matter or exclusivity barrier in the United States. Its investment case depends on niche hospital demand, manufacturing reliability, regulatory availability, and supply-chain execution rather than patent protection. The principal risks are weak clinical relevance, narrow use, adverse-effect liabilities, low pricing power, and competition from supportive ventilation, naloxone, caffeine citrate, and other respiratory-management approaches.

Doxapram Hydrochloride Investment Analysis, Patent Status, FDA Regulation, and Market Fundamentals

What is the investment thesis for doxapram hydrochloride?

Doxapram hydrochloride is a legacy central respiratory stimulant administered primarily by injection. It increases respiratory drive through central nervous system stimulation and peripheral carotid-body effects. Its labeled uses have included postoperative respiratory depression, drug-induced respiratory depression, and selected cases of acute respiratory failure associated with chronic obstructive pulmonary disease (FDA, 2010).

The investment thesis is defensive rather than growth-oriented:

Factor	Assessment
Patent protection	Effectively expired for the active ingredient and core injectable use
FDA exclusivity	No meaningful current exclusivity identified
Product type	Legacy injectable hospital drug
Pricing power	Low to moderate, depending on supplier concentration
Clinical differentiation	Limited
Manufacturing barriers	Moderate because sterile injectable production is difficult
Generic entry risk	High
Biosimilar risk	Not applicable
Commercial growth	Limited without a new formulation or new indication
Strategic value	Potential niche supply asset, not a conventional innovation asset

Doxapram may have value in a shortage-prone hospital market if a manufacturer controls a reliable sterile injectable supply. That value would arise from operational scarcity, not from patent-backed market exclusivity.

What patents protect doxapram hydrochloride?

The original doxapram molecule and its pharmaceutical use were developed many decades ago. The relevant composition, process, and basic formulation rights would have expired long before the current generic market.

No active United States patent estate with material commercial scope is associated with the core doxapram hydrochloride injection product in the FDA records and public product information used for this analysis. The commercial product therefore does not have the structure of a modern specialty pharmaceutical protected by overlapping composition, formulation, method-of-use, and manufacturing patents.

Patent estate assessment

Patent category	Commercial status for doxapram hydrochloride
Composition of matter	Expired
Basic pharmaceutical formulation	Expired or no longer commercially relevant
Injectable product claims	No meaningful active exclusivity identified
Method-of-use claims	Legacy rights expired; no current blocking estate identified
Manufacturing patents	No publicly prominent blocking portfolio associated with the marketed drug
Pediatric exclusivity	None identified
Orphan-drug exclusivity	None identified
New chemical entity exclusivity	Expired decades ago

The absence of active patents does not eliminate regulatory or manufacturing barriers. A company still must meet current FDA requirements for sterile injectable production, chemistry, manufacturing and controls, labeling, pharmacovigilance, and facility compliance.

When does doxapram hydrochloride lose exclusivity?

Doxapram lost meaningful exclusivity decades ago. Its current competitive position reflects an off-patent injectable market rather than a product approaching patent expiry.

The relevant timeline is:

Event	Timing or status
Original development and approval	Legacy product; approval predates the modern Hatch-Waxman framework
Core patent protection	Expired
FDA marketing exclusivity	Expired
Generic availability	Established or historically established
Current blocking patents	None with evident material scope
Current market status	Legacy product with intermittent commercial availability

The investment question is therefore not when exclusivity ends. It is whether demand and supply conditions create sufficient returns despite generic competition.

What is the FDA regulatory status of doxapram hydrochloride?

Doxapram hydrochloride has been marketed in the United States as an injectable prescription drug. The historical reference product is Dopram, associated with A.H. Robins. FDA labeling identifies doxapram hydrochloride injection as a respiratory stimulant for selected forms of respiratory depression (FDA, 2010).

The FDA regulatory profile has several commercial implications:

1. The product is an established drug rather than a new molecular entity.
2. Approval depends on the abbreviated-drug or legacy-drug framework applicable to the specific product and application.
3. The product requires sterile injectable manufacturing.
4. Label limitations and adverse-effect warnings restrict broad substitution for modern respiratory-support practices.
5. FDA approval does not guarantee continuous commercial supply.

Drugs@FDA records should be used to verify the current application holder, marketing status, approval history, and any discontinuation designation for a specific product presentation (FDA, n.d.-a).

What is the Orange Book status of doxapram hydrochloride?

Doxapram hydrochloride does not have the Orange Book profile of a branded product protected by current listed patents or exclusivity. The Orange Book should be checked by active ingredient, dosage form, and strength because FDA listing status can vary by product and application (FDA, n.d.-b).

For investment purposes, the relevant conclusion is straightforward: a generic applicant would not face a conventional Paragraph IV challenge against a live doxapram composition patent. Any regulatory competition would more likely involve ANDA approval, manufacturing readiness, bioequivalence or pharmaceutical-equivalence requirements, and commercial launch economics.

How many patents cover doxapram hydrochloride?

No material active United States patent portfolio covering the core doxapram hydrochloride injection product has been identified in the public FDA product framework. The practical count of commercially blocking patents is therefore zero or immaterial.

A historical patent search may return older patents involving:

• Doxapram chemical synthesis.
• Early pharmaceutical compositions.
• Respiratory-stimulant uses.
• Related salts or dosage forms.
• Foreign filings and abandoned applications.

Historical records should not be confused with enforceable rights. For diligence, the relevant test is whether a patent is unexpired, enforceable in the target country, broad enough to cover the proposed product, and owned by a party capable of enforcing it.

What formulations are protected by doxapram patents?

The commercial product is principally an injectable solution, commonly identified as doxapram hydrochloride injection at a concentration of 20 mg/mL. The formulation is a conventional sterile injectable product rather than a delivery system with a recognized proprietary platform.

Potential formulation opportunities include:

• Ready-to-use vials.
• Prefilled syringes.
• Improved preservative systems.
• Stability-enhanced presentations.
• Premixed hospital products.
• Alternative parenteral concentrations.
• Controlled-release or noninjectable respiratory-stimulant formulations.

These concepts could support new patent filings only if they satisfy novelty, nonobviousness, enablement, and commercial utility standards. A new presentation would also require FDA review and could face rapid generic design-around activity.

The strongest potential barrier is likely manufacturing know-how around sterile filling, container closure, stability, and supply qualification. That barrier is operational and regulatory, not necessarily patent-based.

Are there method-of-use patents for doxapram hydrochloride?

No current method-of-use patent estate with clear commercial blocking effect is associated with the established labeled uses of doxapram hydrochloride. The principal indications are old and clinically familiar.

A new method-of-use program could target a narrowly defined population or treatment setting, but its value would depend on:

• A clinically meaningful treatment effect.
• A population with few alternatives.
• Prospective clinical evidence.
• A label that supports enforcement.
• Prescriber willingness to use doxapram instead of ventilation or other therapies.

Method-of-use protection would also face challenges in proving induced infringement where physicians use the drug for multiple established purposes.

Which companies are challenging doxapram hydrochloride exclusivity?

No major current Paragraph IV campaign has been publicly associated with doxapram hydrochloride. The drug is too old and commercially narrow to attract the type of patent challenge seen with high-revenue branded products.

The competitive threat comes from generic manufacturers and hospital suppliers that can enter or re-enter the market once they have:

• An approved application.
• Qualified sterile injectable capacity.
• Reliable active pharmaceutical ingredient supply.
• Acceptable economics at generic pricing.
• Distribution agreements with hospitals and wholesalers.

Because the core rights are expired, competition does not require a patent invalidity campaign. A new entrant can compete through regulatory approval and supply execution.

What patent litigation affects doxapram hydrochloride?

No material ongoing United States patent litigation affecting the core doxapram hydrochloride injection market is identified in the standard public regulatory and patent framework.

The absence of litigation is itself commercially relevant. It indicates that value is unlikely to be created through enforcement, settlement payments, or a protected launch window. It also means an acquirer would not inherit a known patent-litigation catalyst comparable to those associated with branded oncology, immunology, or rare-disease products.

Potential disputes would more likely involve:

• Product quality.
• Manufacturing deviations.
• Labeling.
• Distribution contracts.
• Drug shortages.
• Regulatory compliance.
• Trademark or trade-name rights.

What generic entry risks exist for doxapram hydrochloride?

Generic entry risk is high because the drug is mature and the core intellectual property is expired. Entry could pressure price, especially if more than one supplier has approved sterile injectable capacity.

The market has an important qualification: sterile injectable entry can be slow and expensive. A nominally open market may still have few active suppliers because of:

• Complex aseptic processing.
• High inspection and validation costs.
• Small batch sizes.
• Low expected revenue.
• Active pharmaceutical ingredient constraints.
• Hospital contracting requirements.
• Product-specific stability and container-closure requirements.

This creates a two-level risk profile:

Risk	Effect
Patent risk	Low barrier to entry
Regulatory risk	Moderate
Manufacturing risk	Moderate to high
Price erosion risk	High if multiple suppliers enter
Shortage risk	Material if one supplier exits
Substitution risk	High from alternative clinical practices

A supplier with only one manufacturing site would carry meaningful interruption risk. A supplier with dual-site production, qualified API sources, and established hospital distribution would have a stronger commercial position.

Is biosimilar risk relevant to doxapram hydrochloride?

No. Doxapram hydrochloride is a small-molecule drug, not a biologic. Biosimilar competition under the Public Health Service Act is therefore not applicable.

The relevant pathway is generic competition under the Federal Food, Drug, and Cosmetic Act, normally through an abbreviated new drug application where the product and regulatory history support that route (FDA, n.d.-c).

How does doxapram compare with competing respiratory therapies?

Doxapram competes with clinical interventions rather than only with chemically similar drugs.

Alternative	Primary use	Competitive effect
Naloxone	Opioid-induced respiratory depression	Strong substitute when opioids are the cause
Caffeine citrate	Apnea of prematurity	Preferred in neonatal care
Noninvasive ventilation	Acute respiratory failure	Reduces need for pharmacologic stimulation
Mechanical ventilation	Severe respiratory insufficiency	Replaces drug-based respiratory stimulation
Doxapram	Selected respiratory depression and COPD-related settings	Narrow role
Supportive monitoring and airway management	Postoperative care	Limits routine use

Doxapram’s commercial weakness is that many causes of respiratory depression have more targeted or better-established interventions. Naloxone directly reverses opioid effects. Ventilatory support treats the physiologic problem without relying on central stimulation. Caffeine citrate has a defined neonatal role and a stronger modern evidence base in that setting.

What licensing deals involve doxapram hydrochloride?

No major current licensing transaction has been identified as a central value driver for doxapram hydrochloride. The drug’s commercial history is associated with legacy ownership and generic or hospital-supply distribution rather than platform licensing.

A transaction involving the product would more likely take one of these forms:

• Acquisition of an approved injectable product.
• Transfer of an abbreviated application.
• Contract manufacturing.
• Regional distribution rights.
• Hospital-supply agreement.
• Acquisition of an established sterile injectable facility.

The value of such a deal would depend on net sales, manufacturing cost, product availability, regulatory history, and supply contracts. Patent life would contribute little or nothing to valuation.

What is the revenue exposure for a doxapram hydrochloride investment?

Doxapram is unlikely to support large branded-drug revenue without a new indication or delivery technology. Its revenue base is constrained by:

• Narrow labeled use.
• Low treatment frequency.
• Generic pricing.
• Clinical substitution.
• Hospital procurement pressure.
• Limited physician demand.
• Potentially inconsistent availability.

A financial model should focus on supply reliability rather than peak-sales projections. Key variables include:

Variable	Investment relevance
Annual units sold	Determines manufacturing scale
Net price per vial	Measures pricing power
Number of active suppliers	Predicts price erosion
Hospital contract duration	Indicates revenue visibility
Gross margin	Captures sterile manufacturing economics
Batch-failure rate	Directly affects profitability
API cost	Controls cost of goods
Shortage frequency	Can increase price but raises regulatory scrutiny
Product discontinuation risk	Affects continuity of revenue

A niche supplier could achieve attractive margins during a shortage, but shortage-driven pricing is volatile and may attract new entrants, regulatory attention, or hospital substitution.

How strong is the patent estate for doxapram hydrochloride?

The patent estate is weak for investment purposes. Doxapram lacks the characteristics that support a patent-led pharmaceutical valuation:

• No current composition patent.
• No evident blocking formulation patent.
• No active exclusivity period.
• No meaningful patent litigation catalyst.
• No biosimilar framework.
• No established license network tied to proprietary technology.

Its defensibility is better described as a supply and regulatory moat. That moat can still be valuable, but it is vulnerable to a competitor that qualifies another sterile injectable facility or acquires an approved application.

What are the likely generic launch scenarios?

Scenario 1: Single-supplier niche market

One supplier maintains approval and reliable production. Pricing remains stable because hospitals value continuity. This is the most favorable scenario for an incumbent but remains exposed to manufacturing disruption.

Scenario 2: Two or more approved suppliers

Price competition increases. Hospital buyers gain leverage, and revenue falls unless the incumbent has superior availability, service, or contracts.

Scenario 3: Product shortage

A supplier interruption creates temporary pricing power and possible emergency sourcing. The benefit may be short-lived, and the interruption can reduce confidence in the product.

Scenario 4: Clinical substitution

Hospitals reduce use in favor of ventilation, naloxone, or other therapies. Demand contracts even without new generic entry.

Scenario 5: Reformulation or new indication

A sponsor develops a new dosage form or clinically differentiated use. This is the only scenario that could support meaningful new intellectual-property value, but it requires clinical and regulatory investment disproportionate to the existing market unless a high-value niche is identified.

What geographic coverage applies to doxapram hydrochloride?

Patent protection for the original molecule is expired in the major pharmaceutical markets. Current commercial opportunities are therefore jurisdiction-specific and depend on:

• National marketing authorization.
• Local sterile manufacturing rules.
• Import requirements.
• Government procurement.
• Hospital formularies.
• Local shortage conditions.
• Active supplier count.

The United States offers a regulated generic market with FDA manufacturing obligations. Europe and other regions require separate regulatory and pharmacopoeial compliance. A product’s approval in one jurisdiction does not establish automatic marketing rights elsewhere.

What is the final investment view on doxapram hydrochloride?

Doxapram hydrochloride is a low-growth, low-patent-value pharmaceutical asset. It may be investable as part of a sterile injectable portfolio, particularly where the buyer has manufacturing capacity, hospital distribution, and the ability to manage shortage-prone products.

It is unattractive as a standalone innovation investment because:

1. Core exclusivity has expired.
2. Clinical use is narrow.
3. Generic entry risk is high.
4. Alternative therapies are widely available.
5. Revenue visibility is likely limited.
6. Product value depends on execution rather than intellectual property.

The strongest acquisition rationale would be access to an approved product, a qualified sterile facility, a stable API supply chain, or a broader hospital-drug portfolio. A patent premium is not justified.

Key takeaways

• Doxapram hydrochloride is an old, off-patent respiratory stimulant.
• Core composition and basic-use rights are expired.
• No material current Orange Book exclusivity or patent barrier is evident.
• Paragraph IV litigation is not a central market risk.
• Biosimilar competition does not apply.
• Generic and clinical-substitution risks are high.
• Sterile manufacturing and supply reliability are the main potential barriers.
• The asset has niche value as a hospital injectable, not as a patent-protected growth product.
• A transaction should be valued on net sales, manufacturing economics, supply continuity, and regulatory status.
• New value would require a differentiated formulation, new indication, or superior supply platform.

FAQs about doxapram hydrochloride investment and exclusivity

Is doxapram hydrochloride still FDA approved?

Doxapram hydrochloride has a long FDA marketing history as an injectable respiratory stimulant. The current status must be assessed by specific product, application holder, strength, and marketing status in Drugs@FDA and the FDA drug-label databases.

Is doxapram hydrochloride listed in the Orange Book?

The drug does not have the profile of a currently patent-protected branded product. Orange Book review should be conducted by active ingredient, dosage form, and strength because application and listing status can differ among products.

Can a company obtain new patents on doxapram hydrochloride?

A company cannot normally extend the expired original composition patent. It may seek new patents for a novel formulation, delivery system, manufacturing process, or method of use if the claims meet U.S. patentability standards.

Is doxapram hydrochloride a controlled substance?

Doxapram is not generally treated as an opioid controlled substance. Its principal regulatory issues relate to prescription status, labeling, adverse effects, and sterile injectable manufacturing.

What is the main commercial risk for a doxapram hydrochloride manufacturer?

The main risk is demand erosion combined with sterile injectable supply costs. A manufacturer can face low volume, limited pricing power, production interruptions, and substitution by naloxone, ventilation, caffeine citrate, or supportive care.

References

1. Food and Drug Administration. (2010). Doxapram hydrochloride injection prescribing information. U.S. Department of Health and Human Services.

2. Food and Drug Administration. (n.d.-a). Drugs@FDA: FDA-approved drugs. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/scripts/cder/daf/

3. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. Food and Drug Administration. (n.d.-c). Abbreviated new drug application (ANDA). U.S. Department of Health and Human Services. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

5. DailyMed. (n.d.). Doxapram hydrochloride injection drug label. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/